Skip to content

Retro Biosciences

StartupUS1 field

Website

Where it works

Technology
Longevity biotechDevelops autophagy drugs, iPSC-derived cell therapies and tissue reprogramming aimed at adding ten healthy years.

Funding

DateRoundAmount
May 22, 2026Initial closeLed by 4P CapitalAmount not disclosed; $1.8B pre-money valuation
About
Source
retro.bio (official, added by seed)
First seen
Sep 25, 2026
Last seen
Sep 25, 2026
DateChange
Sep 25, 2026Retro BiosciencesCompany in Longevity biotech: Joined a field, Develops autophagy drugs, iPSC-derived cell therapies and tissue reprogramming aimed at adding ten healthy years.
Sep 25, 2026Retro BiosciencesCompany: Added

Frontier tech by email

Tuesdays, only in weeks with new milestones, rounds or stage changes in the fields tracked here.

Double opt-in. Unsubscribe any time.